Category: Hepatitis

IAS 2017: Closing ceremony exposes Gilead Sciences

Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the closing...

/ 26 July 2017

HIV Activists Denounce ViiV for Denying 3.5 million People Access to Optimal Treatment

Source : ITPC GLOBAL Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment activists from around the world collectively blocked access to ViiV Healthcare’s promotional booth and stormed its...

/ 24 July 2017

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices

Source : By Frederick M The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. The near-unanimous decision...

/ 1 June 2017

Access to medicines amendment of the WTO TRIPS Agreement– hype or hope?

By: Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl On 30 January the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome entry into force of...

/ 5 April 2017

The HepC Pill Bill

Source : hepCoalition The HepC Pill Bill-An insight into the availability, pricing and accessibility of HCV treatment Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known standard HCV regimen consisted of a...

/ 5 April 2017

Amendment of the TRIPS Agreement

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...

/ 23 January 2017

Civil Society Calls on WHO to Include Report from UN’s High Level Panel on Medicines on WHO Board Agenda

Dear Director General Dr. Margaret Chan Request to include discussion of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines at the next WHO Board meeting As members of the Make Medicines Affordable campaign, and other Civil...

/ 28 February 2016

Morocco: Creation of a collective for t the right to health in the framework of the negotiations of the EU ALECA

At a time when the Kingdom of Morocco and the European Union are preparing to resume negotiations on the "comprehensive and thorough free trade agreement" (FTAA), Moroccan civil society unites to bell Alarm about ALECA's danger of access to generics...

/ 12 January 2016

HCV

Hepatitis C: Hepatitis C virus (HCV), is a major health concern in MENA. A country like Egypt for example has the highest prevalence of HCV in the world. Pakistan has also a significant number of people with HCV infection. In...

/ 1 October 2015

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco

According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered...

/ 26 June 2015